PMID: 8586805Oct 1, 1995Paper

A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries

Journal of Hypertension
L M ShawA M Heagerty

Abstract

To investigate whether, when angiotensin converting enzyme inhibitors are administered to young, genetically hypertension-prone animals, the demonstrated attenuation of blood pressure development and prevention of the structural changes usually observed in small arteries is attributable to the prevention of angiotensin II production. We have treated spontaneously hypertensive rats (SHR) aged 4-20 weeks with either lisinopril (1 or 10 mg/kg) or the angiotensin II receptor antagonist D 8731 (1, 20 or 50 mg/kg). Blood pressure was measured and structural parameters in small arteries from four vascular beds were examined using isometric myography. At age 20 weeks lisinopril had attenuated blood pressure development and prevented cardiac hypertrophy (but not vascular hypertrophy) in a dose-dependent manner. The highest dose of lisinopril had reduced the blood pressure of the SHR to below that of the Wistar-Kyoto (WKY) rats and prevented most structural changes, but there was a slight reduction in body weight in those rats. Comparable blood pressure control with D 8731 was associated with similar structural parameters. The prevention of hypertension-associated vascular structural alteration appears to be dependent upon the degree of ...Continue Reading

Citations

Sep 12, 2000·Current Hypertension Reports·J B Park, E L Schiffrin
Sep 15, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroshi KomatsuHiroyuki Tsutsui
Jul 24, 2001·The American Journal of the Medical Sciences·E L Schiffrin
Mar 13, 2013·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Juan M VélezEsther Ocharán
Apr 23, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·J B ParkE L Schiffrin
Sep 1, 2007·Circulation Research·Sylvia HeenemanMat J A P Daemen
Jul 1, 1997·Journal of Cardiovascular Pharmacology·J S LiE L Schiffrin
Sep 27, 2003·Autonomic & Autacoid Pharmacology·M MoratoA Albino-Teixeira
Oct 3, 1999·Physiological Reviews·J Zicha, J Kunes
Apr 16, 1998·Scandinavian Cardiovascular Journal. Supplement·E L Schiffrin
Jul 22, 2016·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Massimiliano ManciniPaolo G Camici

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.